Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 331.55 INR
Change Today +5.60 / 1.72%
Volume 252.6K
SAPH On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

shasun pharmaceuticals ltd (SAPH) Snapshot

Open
326.80
Previous Close
325.95
Day High
335.00
Day Low
321.25
52 Week High
03/24/15 - 391.50
52 Week Low
05/6/14 - 128.50
Market Cap
19.9B
Average Volume 10 Days
269.4K
EPS TTM
3.99
Shares Outstanding
60.1M
EX-Date
07/30/14
P/E TM
83.1x
Dividend
1.00
Dividend Yield
0.30%
Current Stock Chart for SHASUN PHARMACEUTICALS LTD (SAPH)

Related News

No related news articles were found.

shasun pharmaceuticals ltd (SAPH) Related Businessweek News

No Related Businessweek News Found

shasun pharmaceuticals ltd (SAPH) Details

Shasun Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and enteric coating excipients. The company offers API products in the areas of pain management and musculoskeletal, central nervous system, cardiovascular, hyperphosphataemia, anti-infective, gastrointestinal, gastrointestinal, and other areas, as well as is developing API products in the areas of anti-depressant and anti-Parkinson’s. It is also engaged in the contract research and manufacturing services business, which provides chemistry and analytical services; and offers formulation development and manufacturing services for solid dosage products to pharmaceutical customers. In addition, the company is involved in biotechnology, nanotechnology, bulk substance, and generic drug development and manufacturing. It exports its products to North America, Europe, Asia, and Latin America. The company was formerly known as Shasun Chemicals and Drugs Ltd. Shasun Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Chennai, India.

Founded in 1976

shasun pharmaceuticals ltd (SAPH) Top Compensated Officers

Managing Director, Chief Executive Officer, W...
Total Annual Compensation: 10.1M
Whole-Time Director and Member of Corporate S...
Total Annual Compensation: 6.5M
Wholetime Director and Member of Audit Commit...
Total Annual Compensation: 6.4M
Compensation as of Fiscal Year 2014.

shasun pharmaceuticals ltd (SAPH) Key Developments

Shasun Pharmaceuticals Ltd Appoints Taru Mayur as Director of the Company

Shasun Pharmaceuticals Ltd. has appointed Mrs. Taru Mayur as Director of the company with effect from April 30, 2015.

Shasun Pharmaceuticals Ltd. Announces Audited Consolidated and Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015

Shasun Pharmaceuticals Ltd. announced audited consolidated and standalone earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 3,361.0 million compared to INR 3,465.6 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 276.2 million compared to INR 241.1 million for the same period a year ago. Profit from ordinary activities before tax was INR 270.5 million compared to INR 134.6 million for the same period a year ago. Net profit was INR 221.6 million or INR 3.58 per diluted share before and after extraordinary items compared to net profit of INR 104.0 million or INR 1.84 per basic and diluted share before and after extraordinary items for the same period a year ago. EBITDA was INR 514 million against INR 454 million a year ago. For the full year, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 12,519.5 million compared to INR 11,576.5 million for the same period a year ago. Profit from operations before other income, finance cost and exceptional items was INR 626.2 million compared to INR 415.4 million for the same period a year ago. Profit from ordinary activities before tax was INR 301.7 million compared to INR 229.7 million for the same period a year ago. Net profit was INR 237.6 million or INR 3.89 per diluted share before and after extraordinary items compared to net profit of INR 302.1 million or INR 5.34 per basic and diluted share before and after extraordinary items for the same period a year ago. EBITDA was INR 1,405 million against INR 1,372 million a year ago. For the quarter, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 2,622.8 million compared to INR 2,730.0 million for the same period a year ago. Profit from operations before other income, finance cost and exceptional items was INR 149.3 million compared to INR 216.6 million for the same period a year ago. Profit from ordinary activities before tax was INR 113.8 million compared to INR 140.8 million for the same period a year ago. Net profit was INR 69.0 million or INR 1.11 per diluted share before and after extraordinary items compared to net profit of INR 110.6 million or INR 1.95 per basic and diluted share before and after extraordinary items for the same period a year ago. For the full year, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 10,243.1 million compared to INR 8,816.2 million for the same period a year ago. Profit from operations before other income, finance cost and exceptional items was INR 760.5 million compared to INR 513.0 million for the same period a year ago. Profit from ordinary activities before tax was INR 458.2 million compared to INR 279.5 million for the same period a year ago. Net profit was INR 413.4 million or INR 6.77 per diluted share before and after extraordinary items compared to net profit of INR 352.3 million or INR 6.22 per basic and diluted share before and after extraordinary items for the same period a year ago.

Shasun Pharmaceuticals Ltd to Report Fiscal Year 2015 Results on Apr 30, 2015

Shasun Pharmaceuticals Ltd announced that they will report fiscal year 2015 results on Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAPH:IN 331.55 INR +5.60

SAPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,365 INR +60.60
Dishman Pharmaceuticals & Chemicals Ltd 159.75 INR +0.55
Divi's Laboratories Ltd 1,749 INR -34.95
Jubilant Life Sciences Ltd 183.50 INR +30.05
Piramal Enterprises Ltd 982.20 INR +38.20
View Industry Companies
 

Industry Analysis

SAPH

Industry Average

Valuation SAPH Industry Range
Price/Earnings 81.6x
Price/Sales 1.4x
Price/Book 5.0x
Price/Cash Flow 27.0x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHASUN PHARMACEUTICALS LTD, please visit www.shasun.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.